NeuroSense Therapeutics has entered into a securities purchase agreement on August 6, 2024, for a private placement offering priced at a 10% premium to the market closing price. The company will issue 800,000 ordinary shares and accompanying warrants at $0.75 per unit, with the warrants having a 5-year term and identical exercise price.Notably, company insiders including the CEO, CFO, CMO, and CEO's family members, along with existing shareholders, are participating in this offering. The private placement is expected to close during the week of August 12, 2024, subject to customary closing conditions. Proceeds will be used for general corporate and working capital purposes.The warrants will be immediately exercisable upon issuance and may be exercised on a cashless basis if no effective registration statement is in place. The offering is being conducted under Section 4(a)(2) of the Securities Act and Regulation D exemptions.

NeuroSense Therapeutics has entered into a securities purchase agreement on August 6, 2024, for a private placement offering priced at a 10% premium to the market closing price. The company will issue 800,000 ordinary shares and accompanying warrants at $0.75 per unit, with the warrants having a 5-year term and identical exercise price.Notably, company insiders including the CEO, CFO, CMO, and CEO's family members, along with existing shareholders, are participating in this offering. The private placement is expected to close during the week of August 12, 2024, subject to customary closing conditions. Proceeds will be used for general corporate and working capital purposes.The warrants will be immediately exercisable upon issuance and may be exercised on a cashless basis if no effective registration statement is in place. The offering is being conducted under Section 4(a)(2) of the Securities Act and Regulation D exemptions.